Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, Jackson HC, Huson L, Ward P, Oxford JS, for the Oseltamivir Post Exposure Prophylaxis Investigator Group . Effectiveness of Oseltamivir in Preventing Influenza in Household ContactsA Randomized Controlled Trial. JAMA. 2001;285(6):748–754. doi:10.1001/jama.285.6.748
Author Affiliations: Children's Hospital, Buffalo, NY (Dr Welliver); University of Michigan School of Public Health, Ann Arbor (Dr Monto); Comprehensive Clinical Research, Berlin, NJ (Dr Hassman); Kentucky Pediatric and Adult Research, Bardstown, Ky (Dr Hedrick); Roche Global Development, Welwyn, England (Drs Jackson, Huson, and Ward); and St Bartholomew's and Royal London Hospital School of Medicine and Dentistry, and Retroscreen Virology Ltd, London, England (Dr Oxford). Dr Carewicz is in private practice in Heidelberg, Germany, and Dr Schatteman is in private practice in Drogen, Ghent, Belgium.
Context Influenza virus is easily spread among the household contacts of an
infected person, and prevention of influenza in household contacts can control
spread of influenza in the community.
Objective To investigate the efficacy of oseltamivir in preventing spread of influenza
to household contacts of influenza-infected index cases (ICs).
Design and Setting Randomized, double-blind, placebo-controlled study conducted at 76 centers
in North America and Europe during the winter of 1998-1999.
Participants Three hundred seventy-seven ICs, 163 (43%) of whom had laboratory-confirmed
influenza infection, and 955 household contacts (aged ≥12 years) of all
ICs (415 contacts of influenza-positive ICs).
Interventions Household contacts were randomly assigned by household cluster to take
75 mg of oseltamivir (n = 493) or placebo (n = 462) once daily for 7 days
within 48 hours of symptom onset in the IC. The ICs did not receive antiviral
Main Outcome Measure Clinical influenza in contacts of influenza-positive ICs, confirmed
in a laboratory by detection of virus shedding in nose and throat swabs or
a 4-fold or greater increase in influenza-specific serum antibody titer between
baseline and convalescent serum samples.
Results In contacts of an influenza-positive IC, the overall protective efficacy
of oseltamivir against clinical influenza was 89% for individuals (95% confidence
interval [CI], 67%-97%; P<.001) and 84% for households
(95% CI, 49%-95%; P<.001). In contacts of all
ICs, oseltamivir also significantly reduced incidence of clinical influenza,
with 89% protective efficacy (95% CI, 71%-96%; P<.001).
Viral shedding was inhibited in contacts taking oseltamivir, with 84% protective
efficacy (95% CI, 57%-95%; P<.001). All virus
isolates from oseltamivir recipients retained sensitivity to the active metabolite.
Oseltamivir was well tolerated; gastrointestinal tract effects were reported
with similar frequency in oseltamivir (9.3%) and placebo (7.2%) recipients.
Conclusion In our sample, postexposure prophylaxis with oseltamivir, 75 mg once
daily for 7 days, protected close contacts of influenza-infected persons against
influenza illness, prevented outbreaks within households, and was well tolerated.
Influenza is spread within the community by aerosol infection.1,2 Its incidence is increased in family
contacts of a primary case compared with sources of infection outside the
immediate household.3- 5
Prevention of influenza in family contacts is recognized as a means of controlling
the spread of influenza within communities.6
The M2 inhibitors amantadine and rimantadine have been used with variable
success in postcontact prophylaxis in families and nursing homes,7- 9 but their use is limited
by the rapid development of resistance and, for amantadine, poor tolerance.10- 13 In
addition, these agents have no activity against influenza B. Neuraminidase
inhibitors are a new class of anti-influenza agents that overcome these limitations.14
Oseltamivir (Ro 64-0796) is the orally bioavailable ethyl ester prodrug
of Ro 64-0802, a potent and selective inhibitor of influenza neuraminidase
in vitro.15 Oseltamivir is the first orally
administered neuraminidase inhibitor with demonstrated efficacy in the treatment
of naturally acquired influenza in humans.16
Orally administered oseltamivir protects against experimental influenza in
animals and humans.17- 19
Daily administration of one 75 mg capsule for 6 weeks was effective and well
tolerated in preventing influenza during a seasonal outbreak.20
In this study, we investigated the efficacy of oseltamivir in prevention
of the secondary spread of disease to household contacts of influenza-infected
This cluster-randomized, double-blind, placebo-controlled study was
performed in 76 centers in North America and Europe during community outbreaks
of influenza in the winter of 1998-1999. The study was approved by local institutional
review boards or ethics committees at each center and was conducted in full
compliance with the amended Declaration of Helsinki.21
Each participant provided written informed consent.
Families were informed about this study by means of posters and leaflets
in the participating clinics and from local press advertisements both prior
to and during the influenza season. During the influenza outbreak, family
practitioners recruited eligible households with a minimum of 2 and a maximum
of 8 contacts within 48 hours of symptom onset (minimum cough and coryza)
in a primary (index) case (IC). Children (<12 years) were excluded from
participation as contacts, but households in which other members met the conditions
for eligibility and in which the child was the IC were permitted entry. Households
that contained women who were pregnant or breastfeeding, and any individual
with cancer, immunosuppression, human immunodeficiency virus infection, or
chronic liver or renal disease were also excluded from the study. Household
members with other well-controlled comorbidities and those who were vaccinated
were eligible. Elderly subjects (≥65 years) were required to achieve a
Mental Status Questionnaire score of 7 or higher.22
Nose and throat swabs and a serum sample were collected from all ICs
within 48 hours of symptom onset. The IC did not receive any antiviral therapy.
All ICs were followed up at a clinic visit and serum samples were drawn between
study days 17 and 25.
Before the first dose of study medication, all contacts underwent a
physical examination including vital signs and oral temperature measurement.
Nose and throat swabs for influenza virus culture and a serum sample for influenza-specific
antibodies were taken from all contacts at baseline. Baseline (predose) samples
of blood and urine were collected for routine laboratory tests. All contacts
returned for a physical examination on day 8, and a serum sample and clinic
visit between study days 17 and 25.
Randomization to 75 mg of oseltamivir or matching placebo once daily
for 7 days was by household cluster such that all members of the same family
received the same therapy. The first dose was taken within 48 hours of first
reported symptoms in the IC. Contacts were instructed to take 1 capsule with
water and a light snack at approximately 24-hour intervals, and were provided
with symptom-relief medication (500 mg of acetaminophen) if needed.
Clinical influenza was defined as an oral temperature of 37.2°C
or higher and at least 1 respiratory symptom (cough, nasal congestion, or
sore throat) and at least 1 constitutional symptom (headache, aches/pains,
chills/sweats, or fatigue) occurring in a single 24-hour period. Household
contacts recorded their oral temperatures and completed a checklist to record
the presence of influenza symptoms daily. Nose and throat swabs were collected
from contacts who developed any of the checklist symptoms on days 2 through
8. All ICs had clinical influenza but a subset had laboratory-confirmed infection.
All contacts had to have clinical symptoms and laboratory confirmation to
be classified as having influenza.
The diagnosis of influenza infection in both ICs and contacts was made
either by isolation of influenza virus from nose and throat swabs or detection
of 4-fold or higher increase in influenza-specific hemagglutinin inhibition
assay (HAI) titer between baseline and convalescent serum samples.
Nose and throat swabs in a chilled viral transport medium were eluted
and cryopreserved at a central laboratory within 36 hours of collection from
the subject (Covance, Princeton, NJ). The presence of influenza virus was
confirmed by indirect fluorescent antibody immunofluorescent assay staining
(using monoclonal antibodies [Chemicon International, Temecula, Calif] raised
to influenza A and B nucleoproteins) following incubation of swab eluates
for up to 7 days in rhesus monkey kidney cell cultures (Bio Whittaker, Walkersville,
Convalescent serum samples were taken from all index and contact cases
at study follow-up visits (study days 17-25). Influenza-specific antibody
titers were measured by HAI assay. The method used turkey erythrocytes; the
antigens tested were the virus strains influenza A/Sydney/5/97(H3N2), A/Beijing/262/95(H1N1),
and B/Beijing/184/93 (ViroMed Laboratories, Minneapolis, Minn).
Secreted neuraminidase enzyme in all influenza virus–positive
culture supernatants was examined for sensitivity to inhibition by the active
metabolite, Ro64-0802 (GS4071) (Hoffmann-La Roche, Basel, Switzerland, data
The population for safety analysis included all randomized contacts
who received at least 1 dose of study drug and at least 1 safety follow-up
even if he/she was withdrawn prematurely. Efficacy analyses were performed
on 2 populations: contacts of all ICs and contacts of influenza-positive ICs.
Contacts of all ICs were defined as those who were randomized, received at
least 1 dose of study medication, and reported efficacy data with or without
a confirmed influenza-positive IC. Contacts of an influenza-positive IC were
defined as those who were randomized, had efficacy data, received at least
1 dose of study medication, and with a confirmed influenza-positive IC.
The primary efficacy end point was the proportion of contacts of an
influenza-positive IC with laboratory-confirmed clinical influenza during
the dosing period (study days 1-7 inclusive). The active and the placebo groups
were compared using χ2 tests and test-based confidence intervals
(CIs) adjusted to take into account the probable intracluster correlation
in end point incidence.23
Other analyses comparing numbers of contacts meeting a given end point
used χ2 tests and CIs adjusted to take into account the probable
intracluster correlation in end-point incidence. Analyses comparing numbers
of infected households/families used Fisher exact test. The level of significance
A total of 377 households (comprising 962 potential contacts) were enrolled.
The majority (>90%) of households consisted of family groups; the remainder
were groups of students or young adults. There were 955 eligible contacts
of all ICs (99%) in 371 households (Figure
1). The 7 excluded persons did not take any trial medication. One
percent of these contacts (12/955) were shedding influenza virus at baseline.
Of the 377 ICs, 163 (43%) had laboratory-confirmed influenza. This is
a lower frequency of infection than observed during oseltamivir treatment
studies (60%); however, in those studies the case definition also included
body temperature of 38°C or higher.16 The
mean age of influenza-infected ICs was 27 years (range, 1-76 years). Ten percent
(16/163) were children younger than 11 years (2.5% [4/163] were <5 years),
33% (54/163) were adolescents (12-17 years), and the remainder were older
than 18 years, reflecting the recruitment focus on families with teenage siblings
(≥12 years). There were 415 contacts in the 163 households in which the
IC had laboratory-confirmed influenza infection (Figure 1, Table 1).
This subset of contacts included 10 subjects (6 received placebo and 4 oseltamivir)
who were already shedding influenza virus at baseline. Five of these were
asymptomatic (4 placebo and 1 oseltamivir) and remained asymptomatic throughout
the study. Three (2 placebo and 1 oseltamivir) had low-grade symptoms that
did not meet the case definition at entry; none developed an illness meeting
the case definition during the study. One (who received oseltamivir) met the
case definition at study entry and was admitted in violation of the protocol.
One other subject had fever at entry and developed an illness meeting the
case definition on day 2 of oseltamivir prophylaxis.
The difference between the 2 populations (955 minus 415) identifies
the 540 subjects who were household contacts of ICs who were not subsequently
confirmed to have influenza infection (contacts of an influenza-negative IC; Figure 1). These individuals were, nevertheless,
likely to have been exposed to influenza virus outside the household in the
Assignment of household contacts to placebo or active drug is shown
in Figure 1. In both analysis populations
(contacts of all ICs and contacts of an influenza-positive IC), the comparator
groups were well-matched, both demographically and in immune status (Table 2).
Both influenza types A and B were circulating during the study; 86 (53%)
of 163 infected ICs had laboratory evidence of infection with influenza A.
Laboratory evidence of infection with both type A and B viruses in the same
household was infrequent (3% of households).
Protective efficacy of oseltamivir was determined on the basis of the
number of individuals and households exposed to all ICs (Table 1). Protective efficacy in this situation was very high, 89%
for individuals (95% CI, 71%-96%; P<.001) and
86% for households (95% CI, 60%-95%; P<.001) (Table 1). The minor difference between
the 2 estimates reflects the effect of multiple clinical cases in single households.
In the contacts of all ICs who received oseltamivir, all cases of laboratory-confirmed
clinical influenza occurred in separate households, whereas for those taking
placebo multiple cases occurred in 7 of the 26 affected households (Table 1), possibly as a result of the prolonged
exposure afforded by the second household case.
Oseltamivir demonstrated the same high-protective efficacy in contacts
of infected ICs. In this population, the incidence of laboratory-confirmed
clinical influenza in individuals and households receiving oseltamivir during
the 7-day prophylaxis period was reduced by 89% (95% CI, 67%-97%; P<.001) and 84% (95% CI, 49%-95%; P<.001),
respectively (Table 1). Five contacts
in the 163 households developed influenza due to a virus type that was different
from that detected in the IC. These individuals probably acquired influenza
infection from contact with a case outside the home environment.
There was a larger number of influenza cases reported in the contacts
of all ICs compared with contacts of an influenza-positive IC (Table 1). Of 540 contacts of an influenza-negative IC, 3.1% (8/256)
of placebo recipients developed laboratory-confirmed clinical influenza compared
with only 0.4% (1/284) of oseltamivir recipients. Protective efficacy for
individuals exposed to influenza outside the household was therefore also
89% (95% CI, 10%-99%; P = .009) (Table 1).
Twenty-one of the clinical cases among the placebo recipients were infected
with influenza A and 13 with influenza B virus. None of the clinical cases
in the group of oseltamivir-treated contacts was infected with influenza A
virus. The protective efficacy against influenza B illness in contacts of
all ICs was 78.5% (P = .02).
Households were followed up between study days 10 and 18 after the last
day of study medication. Only 2 new cases of laboratory-confirmed clinical
influenza (1 placebo and 1 oseltamivir) occurred during follow-up; these were
likely due to exposure during the off-prophylaxis period.
Since 10 subjects among the contacts of an influenza-positive IC were
confirmed to be shedding virus prior to the first dose of study medication,
an additional analysis of the primary end point was made excluding these individuals.
In this analysis, 24 (12%) of 200 contacts in the placebo group developed
clinical influenza compared with 2 (1%) of 205 oseltamivir recipients. The
protective efficacy of oseltamivir in this population was 92% (95% CI, 71%-98%; P<.001) for prevention of clinical influenza.
An additional analysis examined only those individuals who were shedding
virus and therefore more likely to transmit influenza to others. The frequency
of viral shedding during the study period was significantly reduced in oseltamivir
recipients (4/209 contacts of an influenza-positive IC and 5/493 contacts
of all ICs) compared with placebo (24/206 contacts of an influenza-positive
IC and 30/462 contacts of all ICs). The protective efficacy in contacts of
an influenza-positive IC was 84% (95% CI, 57%-95%; P<.001).
No isolates from patients who shed virus demonstrated reduced sensitivity
to the active metabolite of oseltamivir.
Laboratory evidence of influenza infection (whether confirmed by viral
shedding or seroconversion) in both symptomatic and asymptomatic contacts
was reduced with oseltamivir (16/209 contacts of an influenza-positive IC
with 8 [50%] who were asymptomatic; 33/493 contacts of all ICs with 18 [55%]
who were asymptomatic) compared with placebo (43/206 contacts of an influenza-positive
IC with 7 [16%] who were asymptomatic; 60/462 contacts of all ICs with 14
[23%] who were asymptomatic). A protective efficacy of 63% (95% CI, 40%-80%; P = .003) was found for contacts of an influenza-positive
IC and 49% (95% CI, 25%-67%; P = .007) for contacts
of all ICs (Table 3).
The dosage of 75 mg of oseltamivir once daily for 7 days was well tolerated.
Gastrointestinal tract effects were reported with similar frequency in recipients
of oseltamivir (9.3% [46/494]) and placebo (7.2% [33/461]). Nausea, which
was reported by 5.5% (27/494) of oseltamivir and 2.6% (12/461) of placebo
recipients, was predominantly mild and transient. There were no abnormal shifts
in laboratory measures of safety or vital signs and no serious adverse events
in those receiving treatment. Withdrawal rates due to adverse events were
low in both groups: 5 (1%) of 494 receiving oseltamivir and 2 (0.4%) of 461
receiving placebo. The 2 placebo subjects (who withdrew on developing an influenzalike
illness) had influenza virus identified from nose and throat swabs collected
on the day of withdrawal. In the oseltamivir-treated group, 2 subjects withdrew
after developing bronchitis on day 6 (neither had influenza infection), 1
for headache, 1 for vomiting, and 1 for dyspepsia.
When one family member develops influenza, others in the family are
known to be at heightened risk of being infected. In this study, the risk
of infection within the household was 20%. Also, the period at risk is generally
at a time when the outbreaks are continuing in the community, so new introductions
of infection into families are also possible. Whatever the source of infection,
this study shows that oseltamivir prophylaxis resulted in significant reductions
in influenza illness in contacts. This was the case whether the end point
was based on numbers of individuals or numbers of households with additional
As in previous studies with antiviral agents (and in line with the mode
of action of neuraminidase inhibitors), efficacy in preventing clinical influenza
(89%) was greater than preventing initial viral infection (63%). Fifty percent
of the subjects in the oseltamivir group who became infected with influenza
remained asymptomatic compared with 16% of those taking placebo. These data
again demonstrate that curtailing viral replication early following infection
effectively prevents the development of clinical disease.20,24
Virus shedding was also significantly reduced, thus reducing the potential
for further spread of influenza within the household.
The reduction in the incidence of clinical influenza by oseltamivir
occurred whether the source of infection was identified within the household
or not (89% protective efficacy in both cases). This suggests that oseltamivir
is equally effective at preventing clinical influenza whether primary exposure
occurs within the family or outside the household in the wider community.
Furthermore, this substantial level of protection was achieved without treating
the IC, thereby maximizing exposure of contacts to influenza. These data corroborate
the 92% protective efficacy of oseltamivir demonstrated in elderly persons
(64-96 years) in skilled nursing homes24 and
a 6-week seasonal prophylaxis study carried out in healthy adults (aged 18-65
The virus isolation rate in the oseltamivir-treated group was low and
none of the isolates were resistant to the carboxylate. As the IC was not
treated in this study, the possibility of transmission of resistant virus,
as described in a similar study with rimantadine,12
could not be studied. The incidence of emergence of virus resistance to neuraminidase
inhibitors is low16,25 and, in
contrast to rimantadine-resistant viruses that retain full infectivity,26 resultant viral mutants are 100- to 1000-fold less
infectious than wild-type virus in animal studies.27
Given the low frequency of resistance to neuraminidase inhibitors and the
reduced infectivity of the viruses detected to date, transmission seems unlikely
to occur in practice, although this needs to be confirmed by further study.
The 84% level of protection afforded by oseltamivir to families in our
study compares with the 72% protection achieved using the inhaled neuraminidase
inhibitor zanamivir in a similar household study.28
In the zanamivir study, prophylaxis was initiated within a narrower window
(36 hours) of symptom onset in the IC. In addition, that study gave drug or
placebo to the IC for 5 days and gave contacts drug or placebo for 10 days
compared with a 7-day treatment course in our study. Furthermore, since in
the zanamivir study all household members, whether ICs or contacts, were placed
together with drug or placebo, it is impossible to say how much of the preventive
effect seen in the contacts was due to actual prophylaxis by the drug or how
much was related to reduction in viral shedding in the IC. Since oseltamivir
is now approved for prophylaxis as well as treatment, a physician can elect
to treat or not treat the IC with oseltamivir, but still prescribe oseltamivir
for household contacts.
A limitation of this study was the inability to include children younger
than 13 years at the time it was conducted. Reduction of virus transmission
in children should be an aim of family prophylaxis, and its importance was
most recently emphasized by the study by Hurwitz et al29
involving the influenza vaccine. The recent demonstration of efficacy30 of oseltamivir in the treatment of influenza in children
aged 1 to 12 years suggests that the protective efficacy in children can be
anticipated to be similar to that demonstrated in adolescents and adults.
Children are important both in the introduction and spread of influenza in
families, and inclusion of such families in a postexposure prophylaxis strategy
will further extend the value of this approach. Only 2.5% of the ICs were
preschool-aged children. Very young children with influenza shed virus for
up to 10 days compared with between 3 and 5 days reported in adults and adolescents.
For this reason, a longer period of prophylaxis may be required in contacts
of infected preschool-aged children to cover the period of risk.
This study demonstrates that 75 mg of oral oseltamivir taken once daily
for 7 days was highly effective in protecting close contacts against influenza
illness when initiated within 48 hours of exposure to a symptomatic case of
influenza and was well tolerated. Oseltamivir effectively prevented further
transmission of influenza within households following prompt initiation of
short-term prophylaxis in families. This occurred even when the IC was not
treated, as would probably occur in many circumstances in clinical practice.
Treating the IC would further reduce the risk of transmission. Use of oseltamivir
short-term will selectively reduce the burden of influenza in those likely
to have been exposed to an IC in their household, a group at particularly
high risk of developing influenza.